BR0114430A - Processos para a indução da morte de células cancerìgenas e para a regressão de tumor - Google Patents
Processos para a indução da morte de células cancerìgenas e para a regressão de tumorInfo
- Publication number
- BR0114430A BR0114430A BR0114430-8A BR0114430A BR0114430A BR 0114430 A BR0114430 A BR 0114430A BR 0114430 A BR0114430 A BR 0114430A BR 0114430 A BR0114430 A BR 0114430A
- Authority
- BR
- Brazil
- Prior art keywords
- cell death
- cancer cell
- processes
- tumor regression
- death induction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"PROCESSOS PARA A INDUçãO DA MORTE DE CéLULAS CANCERìGENAS E PARA A REGRESSãO DE TUMOR". São fornecidos processos para o tratamento de câncer, que compreendem a administração de (1) um inibidor da farnesila proteína transferase em associação com (2) um inibidor adicional da via de sinalização de Ras para induzir a morte de células cancerígenas e a regressão de tumores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23824000P | 2000-10-05 | 2000-10-05 | |
PCT/US2001/042509 WO2002028381A2 (en) | 2000-10-05 | 2001-10-05 | Methods of inducing cancer cell death and tumor regression |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0114430A true BR0114430A (pt) | 2004-01-06 |
Family
ID=22897049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0114430-8A BR0114430A (pt) | 2000-10-05 | 2001-10-05 | Processos para a indução da morte de células cancerìgenas e para a regressão de tumor |
Country Status (14)
Country | Link |
---|---|
US (1) | US6777415B2 (pt) |
EP (1) | EP1322334A2 (pt) |
JP (1) | JP2004510733A (pt) |
CN (1) | CN1479630A (pt) |
AU (2) | AU2002211862B2 (pt) |
BR (1) | BR0114430A (pt) |
CA (1) | CA2424797C (pt) |
HK (1) | HK1052870A1 (pt) |
HU (1) | HUP0302913A3 (pt) |
MX (1) | MXPA03003011A (pt) |
NO (1) | NO20031531L (pt) |
NZ (1) | NZ524936A (pt) |
WO (1) | WO2002028381A2 (pt) |
ZA (1) | ZA200302523B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6369138B2 (en) | 1997-07-11 | 2002-04-09 | Bridgestone Corporation | Processability of silica-filled rubber stocks with reduced hysteresis |
US8791081B2 (en) * | 1999-08-13 | 2014-07-29 | Case Western Reserve University | MGMT inhibitor combination for the treatment of neoplastic disorders |
US20020077301A1 (en) * | 2000-10-05 | 2002-06-20 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
US20040126755A1 (en) * | 2001-08-29 | 2004-07-01 | Stephan Dietrich A | Gene expression based method for distinguishing metastatic from non-metastatic forms of a tumor, and use in designing therapeutic drugs |
US20030185831A1 (en) * | 2001-11-30 | 2003-10-02 | Schering Corporation | Methods of treating cancer using an FPT inhibitor and antineoplastic |
EP1453513A1 (en) * | 2001-12-03 | 2004-09-08 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
US20050004008A1 (en) * | 2002-03-01 | 2005-01-06 | Frackelton A. Raymond | SHC proteins as therapeutic targets in proliferative diseases |
JP4694786B2 (ja) * | 2002-03-01 | 2011-06-08 | ロジャー・ウィリアムズ・ホスピタル | 乳房、前立腺および卵巣の癌の予測のための、Shcタンパク質に関連する方法および組成物 |
US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
US7691905B2 (en) * | 2002-12-24 | 2010-04-06 | New York University | Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA) |
JP2007510661A (ja) * | 2003-11-06 | 2007-04-26 | シェーリング コーポレイション | 乳癌の治療のための、ファルネシルトランスフェラーゼインヒビターと抗ホルモン剤との組合せ |
US20060205810A1 (en) * | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
US20070148660A1 (en) * | 2005-06-16 | 2007-06-28 | The Regents Of The University Of California | Treatment of maladaptive substance use with H-ras antagonists |
JP2009511450A (ja) * | 2005-10-07 | 2009-03-19 | ノバルティス アクチエンゲゼルシャフト | ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ |
AU2006315651A1 (en) * | 2005-11-11 | 2007-05-24 | Roger Williams Hospital | P66-Shc as predictive marker in cancer treatment |
CN102274513B (zh) * | 2011-07-06 | 2013-02-20 | 南开大学 | ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长 |
CN102626416B (zh) * | 2012-05-11 | 2013-04-17 | 江苏省人民医院 | 他莫昔芬联合雷帕霉素、人参皂苷Rg3复合物在制备治疗肝癌药物中的应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2098198A1 (en) | 1990-12-18 | 1992-06-18 | Ann Christie King | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
CA2250232A1 (en) | 1996-04-03 | 1997-10-09 | Allen I. Oliff | A method of treating cancer |
EP0934270A1 (en) * | 1996-05-30 | 1999-08-11 | Merck & Co., Inc. | A method of treating cancer |
EP0991637B1 (en) * | 1997-06-17 | 2002-05-29 | Schering Corporation | Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives as farnesyl protein transferase inhibitors |
WO1998057948A1 (en) * | 1997-06-17 | 1998-12-23 | Schering Corporation | Novel n-substituted urea inhibitors of farnesyl-protein transferase |
US6096757A (en) | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
EP1140938B1 (en) | 1999-01-11 | 2003-08-27 | Princeton University | High affinity inhibitors for target validation and uses thereof |
US6316462B1 (en) * | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
WO2000061142A1 (en) * | 1999-04-14 | 2000-10-19 | Dana-Farber Cancer Institute, Inc. | Method and composition for the treatment of cancer |
US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
US7238525B2 (en) * | 2000-06-30 | 2007-07-03 | The Regents Of The University Of California | Strategy for leukemia therapy |
US20020077301A1 (en) * | 2000-10-05 | 2002-06-20 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
-
2001
- 2001-10-05 AU AU2002211862A patent/AU2002211862B2/en not_active Ceased
- 2001-10-05 AU AU1186202A patent/AU1186202A/xx active Pending
- 2001-10-05 CA CA002424797A patent/CA2424797C/en not_active Expired - Fee Related
- 2001-10-05 CN CNA018201032A patent/CN1479630A/zh active Pending
- 2001-10-05 HU HU0302913A patent/HUP0302913A3/hu unknown
- 2001-10-05 US US09/971,545 patent/US6777415B2/en not_active Expired - Fee Related
- 2001-10-05 WO PCT/US2001/042509 patent/WO2002028381A2/en active IP Right Grant
- 2001-10-05 EP EP01979952A patent/EP1322334A2/en not_active Withdrawn
- 2001-10-05 MX MXPA03003011A patent/MXPA03003011A/es active IP Right Grant
- 2001-10-05 NZ NZ524936A patent/NZ524936A/xx unknown
- 2001-10-05 JP JP2002532206A patent/JP2004510733A/ja active Pending
- 2001-10-05 BR BR0114430-8A patent/BR0114430A/pt not_active IP Right Cessation
-
2003
- 2003-03-31 ZA ZA200302523A patent/ZA200302523B/en unknown
- 2003-04-04 NO NO20031531A patent/NO20031531L/no not_active Application Discontinuation
- 2003-07-12 HK HK03105046.0A patent/HK1052870A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2002028381A2 (en) | 2002-04-11 |
AU1186202A (en) | 2002-04-15 |
HK1052870A1 (zh) | 2003-10-03 |
HUP0302913A2 (hu) | 2003-12-29 |
ZA200302523B (en) | 2004-08-24 |
WO2002028381A3 (en) | 2003-03-27 |
CA2424797A1 (en) | 2002-04-11 |
EP1322334A2 (en) | 2003-07-02 |
NZ524936A (en) | 2005-08-26 |
JP2004510733A (ja) | 2004-04-08 |
AU2002211862B2 (en) | 2007-03-15 |
MXPA03003011A (es) | 2003-07-14 |
US6777415B2 (en) | 2004-08-17 |
HUP0302913A3 (en) | 2005-05-30 |
US20020128280A1 (en) | 2002-09-12 |
CN1479630A (zh) | 2004-03-03 |
CA2424797C (en) | 2009-12-29 |
NO20031531L (no) | 2003-06-05 |
NO20031531D0 (no) | 2003-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0009670A (pt) | Métodos de induzir morte de células de câncer e regressão de tumor | |
BR0114430A (pt) | Processos para a indução da morte de células cancerìgenas e para a regressão de tumor | |
BR9810465A (pt) | Inibidores da farnesiltransferase de proteìnas | |
EA200100111A1 (ru) | Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами | |
BR0013081A (pt) | Pirimidino-2,4,6-trionas inibidoras de metaloproteinases | |
AR027355A1 (es) | Acidos tiazolidincarboxilicos | |
ATE281431T1 (de) | Resorcin-derivate | |
NO20000752L (no) | Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser | |
ATE415161T1 (de) | Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen | |
AR025885A1 (es) | Derivados del acido indolil-3-glioxilico con valiosas propiedades terapeuticas | |
PT1195159E (pt) | Combinacao terapeutica de ascorbato com lisina e arginina para prevencao e tratamento do cancro | |
ES2154693T3 (es) | Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias. | |
BR0317573A (pt) | Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos | |
BR0108728A (pt) | Combinação farmacêutica terapêutica, e, método para tratar um c ncer. | |
BR0315942A (pt) | Tratamento de doenças e condições mediadas pelo aumento de fosforilação | |
BR0213181A (pt) | Combinações de inibidor de cox-2 | |
BR0113165A (pt) | Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados | |
TR200101693T2 (tr) | Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi. | |
PA8506201A1 (es) | Quimioterapia de combinacion (combination chemotherapy) | |
BR9810616A (pt) | Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer | |
PT980205E (pt) | Utilizacao da combinacao de celulas tall-104 com adriamicina ou cisplatina na terapia de tumores malignos | |
ES2164584A1 (es) | Terapia con cannabinoides para el tratamiento de tumores cerebrales. | |
ECSP003417A (es) | Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores | |
TR200302193T4 (tr) | Kombinasyon kemoterapisi. | |
BR0113582A (pt) | Tienopirimidinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009. |